SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada)

Stephen G. Noorduyn 1,2, Christina Qian 3, Karissa M. Johnston 3,4, Mena Soliman 1, Manisha Talukdar 1, Brandie L. Walker 5, Paul Hernandez 6 and Erika Penz 7

1Dept of Medical Affairs, AstraZeneca Canada, Mississauga, Canada. 2Dept of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Canada. 3Broadstreet HEOR, Vancouver, Canada. 4Memorial University, St John’s, Canada. 5Division of Respiratory, Dept of Medicine, University of Calgary, Calgary, Canada. 6Division of Respiratory, Dept of Medicine, Dalhousie University, Halifax, Canada. 7Division of Respiratory, Critical Care and Sleep Medicine, University of Saskatchewan, Saskatoon, Canada.

Corresponding author: Erika Penz (Erika.penz@usask.ca)

Shareable abstract (@ERSpublications)
This longitudinal study supports the recent updates to the CTS and GINA guidelines for asthma care. SABA utilisation can be used to identify patients at higher risk of severe exacerbation, regardless of disease severity. https://bit.ly/3Nd3Uz

Cite this article as: Noorduyn SG, Qian C, Johnston KM, et al. SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada). ERJ Open Res 2022; 8: 00140-2022 [DOI: 10.1183/23120541.00140-2022].

Abstract

Background Patients with asthma use short-acting β-agonists (SABA) to relieve symptoms but SABA alone does not treat underlying inflammation. Thus, over-reliance on SABA may result in poor asthma control and negative health outcomes.

Objective To describe use of SABA and characterise the relationship with severe exacerbations in the Canadian provinces of Nova Scotia (NS) and Alberta (AB).

Methods In this longitudinal Canadian SABA In Asthma (SABINA) study, patients with an asthma diagnosis were identified between 2016 and 2020 within two provincial administrative datasets (Health Data Nova Scotia and Alberta Health Services). All patients were followed for ≥24 months, with the first 12 months used to measure baseline asthma severity. Medication use and the relationship of SABA overuse (three or more canisters per year) with severe asthma exacerbations were characterised descriptively and via regression analysis.

Results A total of 115 478 patients were identified (NS: n=8034; AB: n=107 444). SABA overuse was substantial across both provinces (NS: 39.4%; AB: 28.0%) and across all baseline disease severity categories. Patients in NS with SABA overuse had a mean±SD annual rate of 0.46±1.11 exacerbations, compared to 0.30±1.36 for those using fewer than three canisters of SABA. Patients in AB had mean±SD exacerbation rates of 0.31±0.86 and 0.17±0.62, respectively. The adjusted risk of severe exacerbation was associated with SABA overuse (NS: incidence ratio rate 1.36, 95% CI 1.18–1.56; AB: incidence ratio rate 1.32, 95% CI 1.27–1.38).

Conclusion This study supports recent updates to Canadian Thoracic Society and Global Initiative for Asthma guidelines for asthma care. SABA overuse is associated with increased risk of severe exacerbations and can be used to identify patients at a higher risk for severe exacerbations.

Introduction

Asthma is a chronic disease affecting nearly 10% of Canadians and nearly 65 000 asthma exacerbations occur each year [1–4]. It is estimated that ≥50% of patients with asthma continue to experience exacerbations and regular symptoms throughout their daily life [5, 6]. During periods of poor control, rescue inhalers containing short-acting β-agonists (SABA) are commonly used to relieve acute symptoms, despite leaving the underlying airway inflammation untreated. However, the overuse of SABA (three or more canisters per year) is associated with asthma-related hospital admissions, emergency department visits and an overall increase in healthcare costs [7–20]. Previous studies have found that excessive use (12 or more annual canisters) is even associated with an increased risk of death [19, 21–23].
In 2017, O’Byrne et al. [23] highlighted paradoxes of asthma management. At the time, SABA alone was recommended for patients categorised as Global Initiative for Asthma (GINA) Step One even though asthma is a chronic airway inflammatory disease. O’Byrne et al. [23] noted that when patients progress to GINA Step Two, they initiate regular inhaled corticosteroid (ICS) therapy and are asked to minimise the as-needed SABA upon which they previously relied. This change requires a mindset shift, in which pharmacotherapy is no longer autonomous, symptom-based and associated with fast-acting relief. Instead, patients are expected to adhere to daily or twice daily doses of ICS-based maintenance therapy regardless of their symptoms. However, this means patients do not experience the rapid symptom relief associated with their previous treatment regimen. As a result, they may undervalue adherence to maintenance therapy and simply increase SABA use when symptoms arise. While there have been some targeted studies of the use of SABA in Canada [24], little has been done to quantify the scale of overuse and the impact on patient outcomes.

The SABA in Asthma (SABINA) study is a global programme to evaluate utilisation and clinical outcomes related to SABA use in asthma; this study is the Canadian contribution to that programme [15, 25]. The objectives of this paper were to describe the use of SABA and characterise the relationship with severe exacerbations in the two Canadian provinces of Nova Scotia (NS) and Alberta (AB).

Materials and methods

Study design and data sources

This study is a retrospective cohort study [26] using administrative claims datasets from Health Data Nova Scotia (HDNS) [27] and Alberta Health Services (AHS) [28]. These are provincial health data repositories for nearly one million individuals in NS and over four million individuals in AB. Both datasets include demographics (e.g., sex, date of birth) and administrative claims information on publicly reimbursed health resource use (e.g., medication dispensation, physician visits) and outcomes (e.g., hospital admissions, mortality). Data from both provinces were analysed and reported separately to account for variability in content and coding as well as recognition of data security and privacy requirements from both health systems [29].

Study period definitions

This study used the most recent available data at the time of extraction: from October 2016 to March 2019 for NS, and April 2016 to March 2020 for AB. Three time periods were defined within the study. The baseline period was used to assess case definition and to characterise baseline comorbidity, asthma disease severity, the frequency of asthma-related prescription claims (supplementary table S1), physician visits and exacerbations in the 12 months following the diagnosis meeting the case definition. The index date occurred at the end of the baseline period, or 365 days after the first date on which the patient had an eligible diagnosis, and was used to summarise the age and sex of the patient (supplementary figure S1). The remainder of the follow-up was designated the study period and was used to measure study exposures and outcomes. The study period began at index and ended at the time of censoring, the first occurrence of patients moving out of the province, death or by the end of the study in March 2019 in NS or March 2020 in AB.

Eligibility criteria

Data were linked at the individual level to identify a patient cohort for analysis. Patients who were diagnosed with asthma and had at least two consecutive years of follow-up data were eligible for inclusion [30]. We used a validated case definition for asthma within Canadian administrative datasets (two or more physician visits in a 2-year period or one or more hospital admission with a diagnosis of asthma (International Classification of Disease (ICD) 9th revision, Clinical Modification 493 or ICD 10th revision, Canadian version J45) [31]. Patients were included in the study population if they were ≥12 years old with active records (or known reason for inactivity, e.g., death) throughout the study period. Patients were excluded if they were ≥35 years with a diagnosis of chronic obstructive pulmonary disease, if they had <12 months of data available prior to the index date, if they did not have active asthma (no records of asthma diagnosis or treatment following the index date) or if they had severe asthma and were using biological therapies for disease management (supplementary table S2).

Baseline asthma severity definitions

Asthma severity in the baseline period was determined using average daily dose for ICS (low, medium, high dose) as per the Canadian Thoracic Society (CTS) guidelines [32]. Baseline asthma severity was also categorised into GINA Steps 1–5 per the 2018 GINA recommendations (supplementary material) [33]. Under the CTS definition, patients meeting the case definition but not using any ICS or SABA in the baseline period were included but presented as a distinct subgroup (“mild, no prescription”) throughout the analysis.
Study variables

The exposures of interest included use (i.e. prescriptions dispensed) of ICS and SABA (see supplementary table S1 for included drug identification numbers). ICS in this study refers to all ICS-containing products, i.e. including both ICS monotherapy and ICS/long-acting β-agonist (LABA) combination therapy. SABA dispensations were standardised to a 150-dose canister (for consistency with the global SABINA

| TABLE 1 Patient demographics at baseline among patients with asthma in Nova Scotia and Alberta |
|------------------------------------------------|
| **Primary study cohort** | Nova Scotia | Alberta |
| Subjects, n | 8034 | 107444 |
| Follow-up, median (IQR) (days) | 442 (386–490) | 730 (730–730) |
| Sex, n (%) | | |
| Male | 3171 (39.5) | 46910 (43.7) |
| Female | 4863 (60.5) | 60534 (56.3) |
| Age (years) | | |
| Mean±SD | 43.4±18.3 | 39.7±17.1 |
| Median (IQR) | 43.0 (29.0–57.0) | 38.0 (26.0–52.0) |
| Elixhauser comorbidity score, mean±SD | 2.01±1.27 | 1.21±1.07 |
| Asthma severity, n (%) | | |
| Mild asthma | 6694 (83.3) | 91189 (84.9) |
| Mild, no prescription | 880 (11.0) | 29353 (27.3) |
| Mild, excluding those with no prescription | 5814 (72.4) | 61836 (57.6) |
| Moderate asthma | 998 (12.4) | 10412 (9.7) |
| Severe asthma, no biological treatment | 342 (4.3) | 5843 (5.4) |
| All outpatient visits | | |
| Mean±SD | 1.9±1.3 | 1.6±2.8 |
| Median (IQR) | 2.0 (1.0–2.0) | 1.0 (0.0–2.0) |
| Asthma-specific prescriptions | | |
| Mean±SD | 5.4±5.1 | 5.0±4.5 |
| Median (IQR) | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) |
| Exacerbations, n (%) | | |
| ED visits | | |
| 0 | 7922 (98.6) | 102098 (95.0) |
| 1 | 100 (1.2) | 4341 (4.0) |
| 2 | 11 (0.1) | 709 (0.7) |
| 3 | <5 (0) | 176 (0.2) |
| 4+ | <5 (0) | 62 (0.1) |
| Hospitalisations (excluding ED visits) | | |
| 0 | 8033 (100) | 106303 (98.9) |
| 1 | <5 (0) | 1071 (1.0) |
| 2 | <5 (0) | 58 (0.1) |
| 3 | <5 (0) | 11 (0.0) |
| 4+ | <5 (0) | <5 (0) |
| Prescriptions for OCS | | |
| 0 | 6171 (76.8) | 93070 (86.6) |
| 1 | 1210 (15.1) | 10054 (9.4) |
| 2 | 375 (4.7) | 2501 (2.3) |
| 3 | 129 (1.6) | 882 (0.8) |
| 4+ | 149 (1.9) | 937 (0.9) |
| Severe exacerbations | | |
| 0 | 6149 (76.5) | 95030 (88.4) |
| 1 | 1218 (15.2) | 8855 (8.2) |
| 2 | 381 (4.7) | 2150 (2.0) |
| 3 | 137 (1.7) | 699 (0.7) |
| 4+ | 149 (1.9) | 710 (0.7) |

Cohorts include patients with an asthma diagnosis identified between 2016 and 2020 within two provincial administrative datasets (Health Data Nova Scotia and Alberta Health Services). ED: emergency department; OCS: oral corticosteroid. *: 1 year following diagnosis; #: unique visit dates and/or admission dates; *+: if more than one of the events (hospitalisation or ED with primary diagnosis of asthma, or oral corticosteroid) occurred within a 2-week window, this was counted as one exacerbation.
programme [19, 25]) and annualised over the study period. SABA overuse was defined as three or more canisters per year [17], and 12 or more canisters used per year was considered excessive use [34]. An exploratory analysis using the average number of SABA doses per week was also calculated, defining three or more doses of SABA as “beyond the suggested use”, and 10 or more doses as overuse, as per the CTS guidelines [34]. This alternative quantification permits broader interpretation of the study result in Canadian practice. All dosage calculations assumed that all dispensed medication was completely utilised over the study period [25]. Details of how dispensed prescription medication was used to estimate annual use and weekly use are described in the supplementary material.

Outcomes of interest included severe asthma exacerbations and all-cause mortality. Severe exacerbations were defined by dispensation of short-course (≤10 days) oral corticosteroids (OCS) [35] or by hospital admission or emergency department visit with a primary complaint of asthma (supplementary table S3).

**Ethics approval**

This study received ethical approval from the Health Sciences Research Ethics Boards at Dalhousie University (REB2019-4959/November 29, 2019) and the Health Research Ethics Board of Alberta (REB20-0010/March 5, 2020) for secondary use of information for research. All individual identifiable information was anonymised prior to data analysis and small number subgroups were not reported to prevent identification.

**Statistical analysis**

Patient demographics and baseline characteristics including age, sex, comorbidity burden summarised using the Elixhauser comorbidity score [36] and health-seeking events are presented descriptively. Post-index medication use and exacerbations are also descriptively summarised for the overall cohort and stratified by baseline disease severity and SABA use over the study period. The association between SABA overuse and the number of severe exacerbations was further evaluated by means of a negative binomial regression adjusting for demographic and clinical characteristics. This analysis was limited to the first year of the study period to standardise follow-up available across the two patient populations. The unadjusted and adjusted association between SABA overuse and rate of severe exacerbations was reported using incidence rate ratio (IRR) and 95% confidence intervals, overall and stratified by GINA Step. Subgroup analysis among patients using six or more canisters of ICS (that is, adherent to 50% or more days of maintenance annually) was also performed to stratify patients by maintenance therapy compliance. It should be noted that the number of canisters was used as a measure of compliance rather than the proportion of days covered because it is a more reliable measure for compliance in Canadian claims data [37]. All analyses were limited to available data and no missing data were imputed. All results are reported separately by provincial data source.

**Results**

A total of 115 478 patients was included in the study (NS: n=8034; AB: n=107 444) (supplementary figure S2). At index, patients from NS had slightly higher mean±SD age (NS: 43.4±18.3 years; AB: 39.7±17.1 years) and Elixhauser comorbidity score (NS: 2.01±1.27; AB: 1.21±1.07) than patients from AB (table 1). Commonly observed comorbid diagnoses included anxiety (NS: 16.2%; AB: 27.6%), diabetes (NS: 7.5%; AB: 1.8%), gastro-oesophageal reflux (NS: 4.2%; AB: 0.9%), pneumonia (NS: 4.4%; AB: 4.5%) and bone fractures (NS: 2.4%; AB: 6.6%; supplementary table S4).

**Medication use**

In the baseline period, >80% of both cohorts received no or low-dose ICS, meeting the case definition of mild asthma. Approximately 11% (NS) and 27% (AB) of patients had no asthma-related prescription use in the baseline period. In both cohorts, patients filled a mean±SD of 5±5 asthma medication prescriptions, and had 2±1.3 and 2±2.8 outpatient visits in the baseline period for NS and AB, respectively (table 1).

During the study period, most patients in both provinces received ICS-based maintenance therapy combined with a SABA rescue inhaler (figure 1). In patients who did not fill any prescription during the baseline year, the majority of patients in NS (n=542, 61.6%) also did not receive ICS-containing or SABA medications during the entire study period. Conversely, most patients in AB within this group were dispensed either ICS-containing or SABA medication during the study period (55.8% with SABA monotherapy, 2.5% with ICS-containing therapy and 28.3% with ICS-containing and SABA). Further trends in use of ICS and SABA during the study period are available in table 2 and supplementary table S5, stratified by baseline disease severity defined using CTS and GINA, respectively.
Throughout the study period, between 28% and 39% of patients met the definition of SABA overuse (NS: n=3167, 39.4%; AB: n=30 032, 28.0%) across all baseline disease severity categories. In both provinces, the percentage of patients overusing SABA was associated with baseline severity of disease. Excessive use of SABA was also higher in NS (n=961, 12.0%) than AB (n=3624, 3.4%) and this excessive use of SABA also increased with baseline severity of disease (table 2). In exploratory analyses using dose as the unit of measure, ∼50–60% of patients in both provinces used an average of at least three doses of SABA per week for the study period, indicating use beyond the suggested amount, and the proportion of patients using at least 10 doses per week was comparable to that observed for the overuse definition of three or more canisters per year (figure 2).

**Exacerbations**

Between 10% and 25% of patients experienced a severe exacerbation during the baseline period (NS: n=3167, 24.5%; AB: n=30 032, 9.5%; table 1). During the study period, few patients had any severe exacerbation (NS: 9% of patients; AB: 5%). Annual rates of severe exacerbations increased with SABA use (figure 3) and baseline asthma severity (figure 4 and table 4), with estimates being consistently higher in the NS cohort (tables 3 and 4). Mean±SE estimates of annual exacerbations in NS increased from 0.30±1.36 among patients with appropriate use to 0.46±1.11 among those with SABA overuse and 0.60±1.31 among those with excessive use of SABA. In AB, annual estimates increased from 0.17±0.62 to 0.31±0.86 and 0.49±1.19, respectively. When stratifying by baseline disease severity, in NS, estimates increased from 0.27±1.09 among those with mild asthma (no prescriptions) to 0.81±2.23 among those with severe asthma. In AB, these estimates increased from 0.17±0.66 to 0.34±0.91. A similar trend was noted when baseline disease severity was classified using GINA Steps. Patients defined as GINA Step 5 demonstrated an annual rate of exacerbation six to nine times greater than found in patients of GINA Step 1 (supplementary table S6).
Risk of severe exacerbation in the first year of the study period was higher in patients who overused SABA when adjusted for age, sex and baseline comorbidities (NS: IRR 1.36, 95% CI 1.18–1.56; AB: IRR 1.32, 95% CI 1.27–1.38; figure 5). The effect estimates were consistent between provinces (albeit nonsignificant in NS) among patients with high utilisation of ICS-containing medication (six or more canisters) and when stratified by disease severity (GINA Steps). These effect estimates also remained within bounds of the main analysis, albeit with larger confidence intervals associated with smaller sample size.

**Discussion**

More than 25% of patients with mild asthma were observed to have SABA overuse in the Canadian provinces of NS and AB. SABA overuse was associated with an increased rate of severe exacerbations and this association remained when stratified by ICS use (six or more canisters of ICS per year). The results of the present study are consistent with prior Canadian studies characterising SABA use nearly two decades ago [7] and those describing an association with higher risk of mortality and other poor health outcomes [21, 24, 30]. FITZGERALD et al. [7] identified individuals who used two or more doses of SABA per week in the absence of any ICS or used more than nine canisters of SABA during the year and no more than 100 μg·day<sup>−1</sup> of ICS. They found that inappropriate SABA use was associated with a 45% increased risk of hospital admissions and a 25% increased risk of emergency department visits in the 3-month period following that inappropriate use [7]. In addition, a recent Canadian study including patients ≥65 years of age with prevalent asthma found 14% of patients to have overused SABA (three or more canisters per year) and an associated increased risk of severe asthma exacerbations, ranging from 59–126% among those using three to five canisters and six or more canisters per year [24]. Thus, while definitions of SABA overuse vary in specificity [38], the association between overuse of SABA and poor health outcomes is consistent with the results found in our study.

Internationally, SABA overuse varies from 10% to ∼40% depending on study design [16, 17, 39]. Results from the SABINA participating countries of similar health systems using claims data were comparable to those found in this study [16, 17]. In these countries, the rate of SABA overuse in a real-world setting

**TABLE 2 ICS and SABA use during the study period by baseline disease severity**

| Subjects, n | Nova Scotia | Alberta |
|-------------|-------------|---------|
|             | Overall<sup>a</sup> | Mild, no prescription<sup>b</sup> | Mild, with prescription<sup>c</sup> | Moderate<sup>d</sup> | Severe<sup>e</sup> | Overall<sup>a</sup> | Mild, no prescription<sup>b</sup> | Mild, with prescription<sup>c</sup> | Moderate<sup>d</sup> | Severe<sup>e</sup> |
| ICS dose    |             |             |             |             |             |             |             |             |             |             |
| No ICS      | 3301 (41.1) | 738 (83.9) | 2539 (43.7) | 17 (1.7) | 7 (2.0) | 29 (356) (27.3) | 20 296 (69.1) | 8820 (14.3) | 150 (1.4) | 90 (1.5) |
| Reduced     | 484 (6.0)  | 347 (34.8) | 137 (40.1)  | 7320 (6.8) | 4651 (44.7) | 2669 (45.7) |
| Stable      | 3878 (48.3) | 2960 (50.9) | 582 (58.3) | 198 (57.9) | 66 150 (61.6) | 49 197 (79.6) | 4976 (47.8) | 3084 (52.8) |
| Increased   | 371 (4.6)  | 142 (16.1) | 315 (5.4)  | 52 (5.2)  | 4618 (4.3)  | 9057 (30.9) | 3819 (6.2) | 635 (6.1) |

SABA use (canisters per year)

|          | 0 | 1–2 | 3+  | 12+ |
|----------|---|-----|-----|-----|
| ICS dose |   |     |     |     |
| No ICS   | 2641 (32.9) | 2226 (27.7) | 3167 (39.4) | 961 (12.0) |
| Reduced  | 592 (67.3) | 214 (24.3) | 74 (8.4) | 7 (0.8) |
| Stable   | 1696 (29.2) | 1686 (29) | 2432 (41.8) | 724 (12.5) |
| Increased| 274 (27.5) | 245 (24.5) | 479 (48.0) | 161 (16.1) |

Data presented as n (%), unless otherwise indicated. ICS: inhaled corticosteroids; SABA: short-acting β-agonists. <sup>a</sup>: includes all patients in respective provinces; <sup>b</sup>: includes patients with no prescription dispensed in the baseline period; <sup>c</sup>: includes patients with an average daily dose of ICS that is considered to be a low dose in the baseline period; <sup>d</sup>: includes patients with an average daily dose of ICS that is considered to be a moderate dose in the baseline period; <sup>e</sup>: includes patients with an average daily dose of ICS that is considered to be a high dose in the baseline period.
ranged from 32% (Italy) to 38% (UK), and was associated with a corresponding increased risk of exacerbations of 27% (Italy) and 41% (UK) [16, 17, 40]. While differences in access, policies, healthcare and/or environment may contribute to differences in outcomes, this study observed a rate of SABA overuse ranging from 28% (AB) to 39% (NS) and an estimated adjusted increased risk of severe exacerbations ranging from 32% (AB) to 36% (NS). As such, this study contributes to the body of evidence and supports a common finding of increased risk of exacerbation associated with SABA overuse [38].

![FIGURE 2](https://doi.org/10.1183/23120541.00140-2022)

**FIGURE 2** Overuse and excessive use of short-acting β-agonists (SABA) during the study period, stratified by baseline severity.

| TABLE 3 | Severe exacerbations by SABA use during study period |
|---------|-----------------------------------------------|
| SABA canisters used during the study period in: | Nova Scotia | Alberta |
| Overall | <3 | 3+ | 12+ | Overall | <3 | 3+ | 12+ |
| Subjects, n | 8034 | 4867 | 3167 | 961 | 107 444 | 77 412 | 30 032 | 3624 |
| Annual exacerbations* | | | | | | | | |
| <1 | 7270 (90.5) | 4508 (92.6) | 2762 (87.2) | 811 (84.4) | 98 997 (92.1) | 72 613 (93.8) | 26 384 (87.9) | 2952 (81.5) |
| 1–2 | 391 (4.9) | 192 (3.9) | 199 (6.3) | 59 (6.1) | 6115 (5.7) | 3578 (4.6) | 2537 (8.4) | 406 (11.2) |
| 2+ | 373 (4.6) | 167 (3.4) | 206 (6.5) | 91 (9.5) | 2332 (2.2) | 1221 (1.6) | 1111 (3.7) | 266 (7.3) |
| Mean±SD per patient | 0.36±1.27 | 0.30±1.36 | 0.46±1.11 | 0.60±1.31 | 0.21±0.70 | 0.17±0.62 | 0.31±0.86 | 0.49±1.19 |

Data presented as n (%), unless otherwise indicated. SABA: short-acting β-agonists. *: multiple events (hospitalisation or emergency department visit with primary diagnosis of asthma; oral corticosteroid dispensation; death) within a 2-week window were considered one exacerbation.
FIGURE 3 Number of severe exacerbations by short-acting β-agonists use during the study period. #: if more than one event (hospitalisation or emergency department visit with primary diagnosis of asthma, or oral corticosteroid) occurred within a 2-week window, this was counted as one exacerbation (also included death).

FIGURE 4 Number of severe exacerbations by baseline asthma severity. #: if more than one event (hospitalisation or emergency department visit with primary diagnosis of asthma, or oral corticosteroid) occurred within a 2-week window, this was counted as one exacerbation (also included death); ¶: patients who did not have an inhaled corticosteroid or short-acting β-agonist prescription at anytime throughout the baseline period.
The availability of comprehensive population-based data is a key strength of this study, adding to the generalisability of our results across Canada. In addition, asthma-related prescriptions are comprehensively captured in these data, because SABA can only be dispensed via prescription in Canada. Nonetheless, the use of administrative claims data in this context is also associated with several limitations. Prescription dispensation does not confirm actual use (and the timing of use) of study medications, e.g. patients may 

### TABLE 4 Severe exacerbations by baseline disease severity

| Baseline severity in: | Nova Scotia | Alberta |
|----------------------|-------------|---------|
|                      | Mild, no prescription | Mild, with prescription | Moderate | Severe * | Mild, no prescription | Mild, with prescription | Moderate | Severe * |
| **Subjects, n**      | 880         | 5814    | 998     | 342      | 29,353       | 61,836              | 10,412   | 5843     |
| **Annual exacerbations** |             |         |         |          |             |                     |          |          |
| <1                   | 819 (93.1)  | 5305 (91.2) | 871 (87.3) | 274 (80.4) | 27,607 (94.1) | 56,931 (92.1) | 9390 (90.2) | 5069 (86.8) |
| 1–2                  | 30 (3.4)    | 277 (4.8)   | 61 (6.1)  | 23 (6.7)  | 1288 (4.4)  | 3609 (5.8)    | 710 (6.8)  | 508 (8.7)  |
| ≥3                   | 31 (3.5)    | 232 (4.0)   | 66 (6.6)  | 44 (12.9) | 458 (1.6)   | 1296 (2.1)    | 312 (3.0)  | 266 (4.6)  |
| **Mean ± SD per patient** | 0.27 (1.09) | 0.32 (0.94) | 0.51 (2.25) | 0.81 (2.23) | 0.17 (0.66) | 0.21 (0.66) | 0.25 (0.82) | 0.34 (0.91) |

Data presented as n (%), unless otherwise indicated. *: multiple events (hospitalisation or emergency department visit with primary diagnosis of asthma; oral corticosteroid dispensation; death) within a 2-week window were considered one exacerbation; #: patients with severe asthma not using a biological therapy

The availability of comprehensive population-based data is a key strength of this study, adding to the generalisability of our results across Canada. In addition, asthma-related prescriptions are comprehensively captured in these data, because SABA can only be dispensed via prescription in Canada. Nonetheless, the use of administrative claims data in this context is also associated with several limitations. Prescription dispensation does not confirm actual use (and the timing of use) of study medications, e.g. patients may

### FIGURE 5 Adjusted incidence rate ratio for exacerbations associated with short-acting β-agonist (SABA) overuse (three or more canisters versus fewer than three canisters per year), stratified by baseline disease severity and inhaled corticosteroid (ICS) coverage. Adjusted for age, sex, comorbidities, proportion of days covered by ICS and exacerbation history (number of exacerbations) during the baseline period. GINA: Global Initiative for Asthma.
acquire new inhalers prior to fully utilising prior inhalers. As a result, while associations between SABA overuse and exacerbation outcomes were estimated in this study, causal inference of this relationship is not possible. In addition, claims data do not present additional clinical detail such as a measure of asthma control. As a result, medication and health resource use were used to characterise outcomes and baseline disease severity. Similarly, the dispensation of OCS used to define exacerbations would be subject to the same limitations. Therefore, in the absence of symptom or disease scores, the disease characteristics of these included patients is largely based on dispensed medication rather than actual use and clinical evaluation.

Implications for practice

Several randomised trials have already detailed a reduced risk of severe exacerbations in patients receiving budesonide/formoterol as needed compared to SABA alone, highlighting ICS/LABA as an advantageous combination relative to SABA in patients with mild asthma [41–45]. Among the population of very mild and mild asthma patients, it is now recommended by both GINA and CTS guidelines that patients with poorly controlled asthma or well-controlled asthma at a high risk of exacerbation should be started on daily ICS with as-needed SABA, or budesonide/formoterol as needed [34, 46]. In our study, we found that this guidance would imply an immediate change in treatment strategy for 28% of the AB and 39% of the NS cohort, i.e. those patients who were overusing SABA to manage their asthma symptoms and who were at increased risk of severe exacerbation. As a result, these findings support the recent CTS guidelines for mild to moderate asthma: 1) patients with very mild and mild asthma may still be at risk of severe exacerbations and their disease control should be regularly assessed; 2) SABA use can be used as an indicator of partially controlled or uncontrolled asthma and three or more canisters of SABA in a year is considered overuse; 3) overuse of SABA is associated with a higher risk of exacerbation.

These findings may also have implications for patients with moderate to severe asthma. For these patients, the CTS stratifies by risk of exacerbation and recommends escalation of ICS dose and/or consideration of biological therapy where appropriate. SABA use in these patients may provide a simple indicator with which to estimate asthma control. Indeed, the CTS now includes three or more doses of SABA per week as indicator of partial/uncontrolled asthma.

Primary care providers and specialists may consider implementing these findings by reviewing with their patients the number of doses of SABA used in a week as a simple and objective way to identify patients who have partially controlled or uncontrolled asthma. This approach has also been highlighted by the Health Quality Ontario updated asthma quality standard, which recommends assessing SABA use at least annually with a recommended cut-off of three or more canisters [47].

SABA use is a call to action

Physicians should regularly review SABA use with patients, regardless of disease severity. Pharmacists have a valuable opportunity to identify potential SABA overuse, provide education to patients and offer feedback to prescribing clinicians. Patients should be made aware of the implications of SABA overuse and use this simple metric to help manage their disease and advocate for better care.

Conclusion

More than 25% of patients in this study overused SABA medication during the study period. SABA overuse was associated with increased risk of severe exacerbation outcomes. These findings support the recent updates to the CTS guidelines for asthma care [46], the National Heart, Lung, and Blood Institute and GINA recommendations [48] and the Health Quality Ontario asthma quality standard [47]. Weekly or annual estimates of SABA use represent a simple metric for loss of disease control to physicians, pharmacists and patients and should be considered a simple call to action for all stakeholders.

Acknowledgement: This study acknowledges the contributions of Andrew Fong, who analysed the data made available by Alberta Health Services. Portions of the data used in this report were made available by Health Data Nova Scotia of Dalhousie University. Although this research is based on data obtained from both the Alberta Health Services and the Nova Scotia Dept of Health and Wellness, the observations and opinions expressed are those of the authors and do not represent those of Alberta Health Services, Health Data Nova Scotia or the Nova Scotia Dept of Health and Wellness.

Provenance: Submitted article, peer reviewed.
Consent for publication: The publication of study results was not contingent on the sponsor’s approval or censorship of the manuscript. Funding information for this article has been deposited with the Crossref Funder Registry.

Conflict of Interest: S.G. Noorduyn, M. Soliman and M. Talukdar are employees of AstraZeneca Canada Inc. C. Qian and K. Johnston are employees of Broadstreet HEOR, which received funds from AstraZeneca Canada Inc. for this work. B.L. Walker has received advisory board and speaker’s honoraria from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim and Sanofi, unrelated to this work. P. Hernandez received funding from AstraZeneca to his institution and company for data acquisition and covered costs to conduct the study at the local site. He has received grants paid to his institution from Canadian Institute of Health Research, Boehringer Ingelheim, Cyclomedica, Grifols and Vertex, and received speaker honoraria from AstraZeneca, Boehringer Ingelheim and Janssen. He received honoraria from and participated in advisory boards for Acceleron, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Novartis, Sanofi, Takeda, Teva and Valeo. He volunteered at Canadian Thoracic Society as an executive committee and Board member unrelated to this work. E. Penz has received research funds paid to her institution from AstraZeneca and Saskatchewan Cancer Agency, Canadian Institutes of Health Research, Saskatchewan Health Research Foundation and Respiratory Research Centre unrelated to this work. She has received consulting fees from GlaxoSmithKline, AstraZeneca and Sanofi Genzyme unrelated to this work. She received honoraria for participation on advisory boards, lecture series and educational events from AstraZeneca, GlaxoSmithKline, Sanofi, Boehringer Ingelheim and the International Centre for Evidence-Based Medicine, unrelated to this work. She is a Co-Chair of the COPD Assembly of Canadian Thoracic Society, Medical Lead at the Lung Cancer Screening Prevention Program, Saskatchewan Cancer Agency and a member of the Institute for Cancer Research Advisory Board, Canadian Institute for Health Research.

Support statement: This work was sponsored by AstraZeneca Canada Inc.

References

1. Public Health Agency of Canada. Asthma and Chronic Obstructive Respiratory Disease (COPD) in Canada. Ottawa, ON, Public Health Agency of Canada, 2019.
2. Public Health Agency of Canada. Asthma in Canada. Ottawa, Public Health Agency of Canada, 2018.
3. Public Health Agency of Canada. Fast Facts About Asthma Data Compiled from the 2011 Survey on Living with Chronic Diseases in Canada. Ottawa, Public Health Agency of Canada, 2015.
4. Canadian Institute for Health Information. Emergency Department (ED) Visits: Volumes and Median Length of Stay by Triage Level, Visit Disposition, and Main Problem. Ottawa, Canadian Institute for Health Information, 2017.
5. Quirt J, Hildebrand KJ, Mazza J, et al. Asthma. Allergy Asthma Clin Immunol 2018; 14: 50.
6. FitzGerald JM, Boulet L-P, McVor RA, et al. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J 2006; 13: 253–259.
7. FitzGerald JM, Tavakoli H, Lynd LD, et al. The impact of inappropriate use of short-acting β-agonists in asthma. Respir Med 2017; 131: 135–140.
8. Silver HS, Blanchette CM, Kamble S, et al. Relationship between short-acting β2-adrenergic agonist use and healthcare costs. Am J Manag Care 2011; 17: 19–27.
9. Patel M, Piicher J, Reddel HK, et al. Metrics of salbutamol use as predictors of future adverse outcomes in asthma. Clin Exp Allergy 2013; 43: 1144–1151.
10. Senthilvelan A, Lawson JA, Rennie DC, et al. Regular use of corticosteroids and low use of short-acting β2-agonists can reduce asthma hospitalization. Chest 2005; 127: 1242–1251.
11. Bârnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care 2015; 60: 455–468.
12. Rabe KF, Adachi M, Lai CK, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40–47.
13. Makhinova T, Barner JC, Richards KM, et al. Asthma controller medication adherence, risk of exacerbation, and use of rescue agents among Texas Medicaid patients with persistent asthma. J Manag Care Spec Pharm 2015; 21: 1124–1132.
14. Attar D, Capstick T, Leece D, et al. Healthcare costs associated with short-acting β2-agonist use in asthma: an observational UK study from the SABINA global programme. Eur Respir Soc 2021; 58: PA3525.
15. Bateman ED, Price DB, Wang H-C, et al. Short-acting β2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur Respir J 2022; 59; 2101402.
16. Di Marco F, D’Amato M, Lombardo FP, et al. The burden of short-acting β2-agonist use in asthma: is there an Italian case? An update from SABINA program. Adv Ther 2021; 38: 3816–3830.
17. Janson C, Menzaes-Gow A, Nan C, et al. SABINA: an overview of short-acting β2-agonist use in asthma in European countries. Adv Ther 2020; 37: 1124–1135.
Montero-Arias, F, Carlos Herrera García J, Gallego MP, et al. Overprescription of short-acting β2-agonists in asthma patients from 6 Latin American countries: results from the SABINA international study. Am J Respir Crit Care Med Ther 2021; 30: A1610.

Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J 2020; 55: 1901872.

Price, D, Hancock K, Doan J, et al. Prescriptions of short-acting β2-agonists in patients with asthma in primary care: a SABINA III multicountry analysis. in 10th IPCRG World Conference: Breathing & Living well (2021). https://abdn.pure.elsevier.com/en/publications/prescriptions-of-short-acting-%CE%B22-agonists-in-patients-with-asthma

Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med 1994; 149: 604–610.

Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet 2018; 391: 350–400.

O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? Eur Respir J 2017; 50: 1701103.

To T, Zhu J, Terebessy E, et al. Is Overreliance on SABA Associated with Health Risks in the Older Asthma Population? ERJ Open Res 2022; 8: 00032-2022.

Cabrera CS, Nan C, Lindarck N, et al. SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting β2-agonist use in asthma. Eur Respir J 2020; 55: 1901858.

Schneider B. Analysis of therapeutic efficacy in observational cohort studies. Cancer Chemother Pharmacol 2001; 47: S35–S37.

Dalhousie University. Health Data Nova Scotia. Halifax, NS, Dalhousie University. https://medicine.dal.ca/departments/department-sites/community-health/research/hdns/health-databases.html Date last accessed: July 20, 2022.

Alberta Health, Analytics and Performance Reporting Branch. Overview of Administrative Health Datasets. Edmonton, AB, Government of Alberta, 2017. https://open.alberta.ca/dataset/657ed26d-eb2c-4432-b9cb-0ca2158f165d/resource/38f47433-b33d-4d1e-b959-df312e9d9855/download/research-health-datasets.pdf Date last accessed: July 20, 2022.

Doyle CM, Lix LM, Hemmelgarn BR, et al. Data variability across Canadian administrative health databases: differences in content, coding, and completeness. Pharmacoepidemiol Drug Saf. 2018; 29: 68–77.

Loughheed MD, Lemière C, Ducharme FM, et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir J 2012; 19: 127–164.

Gershon AS, Wang C, Guan J, et al. Identifying patients with physician-diagnosed asthma in health administrative databases. Can Respir J 2009; 16: 183–188.

Loughheed MD, Lemière C, Dell SD, et al. Canadian Thoracic Society Asthma Management Continuum–2010 Consensus Summary for children six years of age and over, and adults. Can Respir J 2010; 17: 15–24.

Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2018. Available from http://ginasthma.org/

GINA. (2020). Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention (Updated 2020). Available from https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf

Reddel H, Barnes D. Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J. 2006; 28: 182–199.

Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8–27.

Blais L, Vilain A, Kettani F-Z, et al. Accuracy of the days’ supply and the number of refills allowed recorded in Québec prescription claims databases for inhaled corticosteroids. BMJ Open 2014; 4: e005903.

Amin S, Soliman M, Mchvor A, et al. Usage patterns of short-acting β2-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunol Pract 2020; 8: 2556–2564.

Vähätalo I, Lehtimäki L, Tuomisto LE, et al. Long-term use of short-acting β2-agonists in patients with adult-onset asthma. J Allergy Clin Immunol Pract 2022, in press.

Quint JK, Armentorp S, Kocks JWH, et al. Short-acting β2-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. J Allergy Clin Immunol Pract 2022; in press.

Bateman ED, Reddel HK, O’Byrne PM, et al. As-needed budesonide–formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018; 378: 1877–1878.

O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide–formoterol as needed in mild asthma. N Engl J Med 2018; 378: 1865–1876.

O’Byrne PM, FitzGerald JM, Bateman ED, et al. Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med 2021; 9: 149–158.

Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 2019; 380: 2020–2030.
45 Hardy J, Baggott C, Fingleton J, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. *Lancet* 2019; 394: 919–928.

46 Yang CL, Hicks EA, Mitchell P, et al. 2021 Canadian Thoracic Society Guideline – a focused update on the management of very mild and mild asthma. *Can J Respir* 2021; 5: 205–245.

47 Ontario Health. Asthma Care in the Community for People 16 Years of Age and Older. Quality Standard. 2020. www.hqontario.ca/Evidence-to-Improve-Care/Quality-Standards/View-all-Quality-Standards/Asthma-in-Adults/The-Quality-Standard-in-Brief Date last accessed: July 20, 2022.

48 Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. *J Allergy Clin Immunol* 2020; 146: 1217–1270.